News

10th Annual Pharma IPR India Conference concludes

The event witnessed the innovative exchange of thoughts with an aim to create an efficient IP framework globally

Informa Pharma Intelligence, the Knowledge Partner of Pharma IPR 2021, recently concluded the 10th Annual Pharma IPR India Conference in congregation with Informa Pharma Intelligence. The event witnessed the innovative exchange of thoughts with an aim to create an efficient IP framework globally to bolster the potential of growth, investments and collaboration amid crises.

THIS CAN BE YOUR ADVERTISEMENT

Announcing the 10th Pharma IPR Conference, Poornachandra Tejasvi, Senior Director, Emerging Markets, India, Informa Pharma Intelligence said, “The Pharma IPR India Conference is an innovative platform to motivate researchers and IP professionals to explore new areas of Pharmaceutical and Biotech innovation, with modern intellectual property strategies, policies, and strong protection are extremely essential, especially amidst the crisis we are in.”

Yogesh Mudras, MD, Informa Markets in India, said, “The pharmaceutical sector is complex and highly regulated in most economies. Recent challenges over patents for varied newer drugs has emphasized that advancement is still required in balancing the opposing forces of innovation through protection of IP rights, versus the provision of affordable drugs for the emerging geographical regions across the globe. IP is the backbone to ensure development of new drugs and is extremely vital to improvise patient care, spurring economic growth and intensifying the innovation economy.”

The conference created a common platform for all key stakeholders, IP/Patent leaders from across India and law firms from across the globe. Based on Informa Pharma Intelligence’s ‘Indian Biosimilars Report’, India leads the way with 127 products, which is the highest number of approved biosimilars compared to other major regions. This is expected to grow further and is likely to shape the next decade for the Indian biosimilars market through intensive portfolio management decisions, pricing, manufacturing prospects, clinical trials and government support.

Amongst the notable members of the advisory board and speakers were Prathiba M Singh, Justice, Delhi High Court, Jacqueline Wright Bonilla, Deputy Chief Administrative Patent Judge, Patent Trial and Appeal Board (PTAB), US Patent and Trademark Office.

 

Support us in our endeavor to bring you Advertisement free content.
Choose your options to donate or subscribe.

Tags

Related Articles

Leave a Reply

Back to top button
Close
Close